On April 12, AVAC and FP2030 convened a consultation with family planning (FP) and sexual and reproductive health (SRH) stakeholders to understand their unique perspectives on the Dual Prevention Pill (DPP), a daily oral pill that prevents HIV and pregnancy. The consultation helped to elevate questions and issues to consider as DPP introduction plans are refined and that can also inform the development and delivery of future multi-purpose prevention technologies (MPTs).